Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early ...

Transforming Growth Factor Beta (TGF‐β) signalling pathways are integral to a wide array of cellular processes, ranging from embryonic development to tissue homeostasis and immune regulation. TGF‐β ...

Transforming growth factor beta (TGF-β) encompasses a family of three related cytokines that orchestrate the cellular and molecular events of wound repair. Upon injury, TGF-β is released from ...

The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...

Pan-tumor circulating tumor DNA testing in the community oncology setting. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.

Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on ...